_version_ 1785090663030718464
author Bazinet, Alexandre
Prasad Desikan, Sai
LI, Ziyi
Venugopal, Sangeetha
Urrutia, Samuel
Montalban-Bravo, Guillermo
Sasaki, Koji
Chien, Kelly
Hammond, Danielle
Kanagal-Shamanna, Rashmi
Mirabella, Bailey
Hendrickson, Stephany
Romero, Liz
Colla, Simona
Ganan-Gomez, Irene
Jose Rodriguez-Sevilla, Juan
Kadia, Tapan
Dinardo, Courtney
Daver, Naval
Jabbour, Elias
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
author_facet Bazinet, Alexandre
Prasad Desikan, Sai
LI, Ziyi
Venugopal, Sangeetha
Urrutia, Samuel
Montalban-Bravo, Guillermo
Sasaki, Koji
Chien, Kelly
Hammond, Danielle
Kanagal-Shamanna, Rashmi
Mirabella, Bailey
Hendrickson, Stephany
Romero, Liz
Colla, Simona
Ganan-Gomez, Irene
Jose Rodriguez-Sevilla, Juan
Kadia, Tapan
Dinardo, Courtney
Daver, Naval
Jabbour, Elias
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
author_sort Bazinet, Alexandre
collection PubMed
description
format Online
Article
Text
id pubmed-10429244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104292442023-08-17 P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX Bazinet, Alexandre Prasad Desikan, Sai LI, Ziyi Venugopal, Sangeetha Urrutia, Samuel Montalban-Bravo, Guillermo Sasaki, Koji Chien, Kelly Hammond, Danielle Kanagal-Shamanna, Rashmi Mirabella, Bailey Hendrickson, Stephany Romero, Liz Colla, Simona Ganan-Gomez, Irene Jose Rodriguez-Sevilla, Juan Kadia, Tapan Dinardo, Courtney Daver, Naval Jabbour, Elias Ravandi, Farhad Kantarjian, Hagop Garcia-Manero, Guillermo Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429244/ http://dx.doi.org/10.1097/01.HS9.0000969796.55461.7b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Bazinet, Alexandre
Prasad Desikan, Sai
LI, Ziyi
Venugopal, Sangeetha
Urrutia, Samuel
Montalban-Bravo, Guillermo
Sasaki, Koji
Chien, Kelly
Hammond, Danielle
Kanagal-Shamanna, Rashmi
Mirabella, Bailey
Hendrickson, Stephany
Romero, Liz
Colla, Simona
Ganan-Gomez, Irene
Jose Rodriguez-Sevilla, Juan
Kadia, Tapan
Dinardo, Courtney
Daver, Naval
Jabbour, Elias
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title_full P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title_fullStr P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title_full_unstemmed P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title_short P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
title_sort p723: clinical and molecular associations with outcomes in higher risk myelodysplastic syndromes treated with hypomethylating agents plus venetoclax
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429244/
http://dx.doi.org/10.1097/01.HS9.0000969796.55461.7b
work_keys_str_mv AT bazinetalexandre p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT prasaddesikansai p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT liziyi p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT venugopalsangeetha p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT urrutiasamuel p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT montalbanbravoguillermo p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT sasakikoji p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT chienkelly p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT hammonddanielle p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT kanagalshamannarashmi p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT mirabellabailey p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT hendricksonstephany p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT romeroliz p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT collasimona p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT ganangomezirene p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT joserodriguezsevillajuan p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT kadiatapan p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT dinardocourtney p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT davernaval p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT jabbourelias p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT ravandifarhad p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT kantarjianhagop p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax
AT garciamaneroguillermo p723clinicalandmolecularassociationswithoutcomesinhigherriskmyelodysplasticsyndromestreatedwithhypomethylatingagentsplusvenetoclax